US Esophageal Cases / Year
~22,000
~80% are incurable at diagnosis. Squamous cell or adenocarcinoma depending on location.[1]
What Is It
Definition, mechanism, and the clinical reality of esophageal and gastric cancer at end of life. What the hospice team needs to understand on day one.
US Gastric Cases / Year
~27,000
5th most common cancer globally. Stage IV median OS ~10–12 months with treatment.[1]
Median OS Post-SEMS
3–6 mo
Inoperable esophageal cancer stented for dysphagia. Hospice enrollment window is critically narrow.[4]
Palliative Referral Rate
<40%
Fewer than 40% of gastroesophageal cancer patients receive specialized palliative care before death.[2]
Two diseases, one trajectory. Esophageal and gastric cancers are managed together in palliative care guidelines because they share anatomical proximity, similar symptom profiles, and converging clinical challenges at end of life — especially at the gastroesophageal junction (GEJ). Both are aggressive, nutrient-depleting malignancies with median survivals measured in months once metastatic.[1]
Histology matters for prognosis: Esophageal squamous cell carcinoma (SCC) predominates in the upper and mid esophagus and is associated with smoking and alcohol. Adenocarcinoma dominates the lower esophagus and GEJ, linked to Barrett's esophagus and GERD. Gastric cancer is predominantly adenocarcinoma, with signet-ring cell type carrying the worst prognosis — a high predilection for peritoneal metastasis, resistance to chemotherapy, and a diffuse infiltrating pattern that makes surgical margins unreliable.[1]
Palliative referral is chronically delayed. Over 60% of gastroesophageal cancer patients die within the first year of diagnosis; nearly 40% die within six months. Yet referral to specialized palliative care often comes late or not at all. Data consistently show these patients need earlier palliative intervention to manage their symptom burden effectively.[2]
🧭 Clinical framing
When you walk into the room of an esophageal or gastric cancer patient, three things will define your visit: they are likely not eating, likely in pain, and the family is likely panicking about both. Start there. The clinical decision tree flows from those three facts.
"Upper GI cancers are gut cancers. They take away the most human thing we do — eat together. Don't underestimate how much meaning is wrapped up in that. The clinical and the emotional are the same problem."
— Waldo, NP · Terminal2
How It's Diagnosed
Diagnostic workup, staging, biomarkers, and what to look for in hospice records. Most patients arrive with an established diagnosis — this section helps you read it.
Diagnostic Workup
- Endoscopy with biopsy: Gold standard for both esophageal and gastric cancer. Establishes histology, location, and degree of luminal obstruction
- CT chest/abdomen/pelvis + PET: Staging — identifies metastatic disease, peritoneal carcinomatosis, liver and lung metastases
- EUS (endoscopic ultrasound): Local staging and lymph node assessment — T and N staging accuracy superior to CT
- HER2 testing: Gastric/GEJ — determines trastuzumab eligibility (ToGA trial). IHC 3+ or IHC 2+/FISH+ is positive
- PD-L1 CPS scoring: Pembrolizumab eligibility in first-line gastric (CPS ≥10 — KEYNOTE-590, CheckMate 649)
- MSI/MMR testing: Identifies microsatellite instability-high tumors responsive to immunotherapy
- VEGFR2: Ramucirumab eligibility for second-line gastric/GEJ adenocarcinoma
What to Look for in Hospice Records
- SEMS placement: Date, type, covered vs uncovered (uncovered has 3.5× higher obstruction risk from tumor ingrowth); dysphagia score at placement[6]
- PEG / feeding tube status: Is it in place? Does the family understand it is not feeding in a curative sense?
- Prior gastric resection extent: Total vs subtotal gastrectomy — affects obstruction anatomy and dumping syndrome
- Peritoneal carcinomatosis on prior imaging: Changes obstruction management approach entirely
- HER2 status: Relevant for family counseling and understanding prior treatment trajectory
- Prior radiation fields: Irradiated esophagus behaves differently in stent management — higher complication rates
- Hemorrhage history: Tumor erosion risk increases as disease progresses; know if prior bleeding events occurred and what intervention was done
📋 Staging Note
Esophageal cancer uses TNM staging (AJCC 8th edition). Gastric cancer uses TNM staging. Know that most patients present at stage III–IV. By the time patients reach hospice, staging is historical context — but it helps you understand what treatments were attempted and why the trajectory unfolded as it did.
Causes & Risk Factors
Modifiable and hereditary risk factors. Relevant for family conversations, genetic counseling referrals, and answering "why did this happen?"
Esophageal Cancer Risk Factors
- SCC — Tobacco + alcohol: Synergistic risk — combined use multiplies risk 30–100×
- SCC — Hot beverage consumption: Repeated thermal injury to esophageal mucosa
- SCC — Nutritional deficiencies: Zinc, selenium; Plummer-Vinson syndrome
- Adenocarcinoma — GERD + Barrett's esophagus: 40–125× increased risk of adenocarcinoma[1]
- Adenocarcinoma — Obesity: Central adiposity; metabolic syndrome
- Adenocarcinoma — Tobacco: Independent risk factor for both subtypes
Gastric Cancer Risk Factors
- H. pylori infection: Most important modifiable risk factor — present in ~75% of gastric cancer. WHO Class I carcinogen[17]
- Smoking: 1.5–2× increased risk
- High sodium/nitrate diet: Salted, smoked, and processed foods
- Prior gastric surgery: Billroth procedures increase risk 15–20 years post-surgery
- Pernicious anemia: Chronic atrophic gastritis → intestinal metaplasia
- Blood type A: Modest association (OR ~1.2)
- CDH1/E-cadherin mutation: Familial diffuse gastric cancer — up to 80% lifetime risk; prophylactic gastrectomy recommended in carriers
❤️ For families: "Why did this happen?"
Families often ask this. There is no single cause. Esophageal and gastric cancers develop from a combination of genetic susceptibility, environmental exposures, and biological changes over many years. This diagnosis was not caused by something your loved one did wrong. It is not punishment. It is biology — and it is not their fault.
⚕ Disparity Note
Gastric cancer disproportionately affects Hispanic, Asian/Pacific Islander, and Black Americans — incidence is 2× higher in Hispanic men than white men. Esophageal SCC disproportionately affects Black Americans; adenocarcinoma disproportionately affects white men. These disparities reflect dietary patterns, H. pylori prevalence, and healthcare access differences.[1]
⚕ Genetic Counseling
CDH1 mutation carriers have up to 80% lifetime risk of diffuse gastric cancer. Even at hospice enrollment, referral for genetic counseling of surviving family members is appropriate if a germline mutation is identified or suspected. This can save lives in the next generation.
Treatments & Procedures
What disease-directed treatments this patient may have received or may still be receiving. Understanding prior therapy helps anticipate complications and interpret the patient's trajectory.
Surgery: Esophagectomy (Ivor Lewis, transhiatal) or total/subtotal gastrectomy. Know what anatomy remains — it affects obstruction presentation, swallowing physiology, and dumping syndrome risk. Prior gastric conduit changes the entire upper GI anatomy.
Chemoradiation: Definitive for esophageal SCC; neoadjuvant for resectable adenocarcinoma (CROSS protocol — carboplatin/paclitaxel + 41.4 Gy; FLOT — 5-FU, leucovorin, oxaliplatin, docetaxel for gastric/GEJ).
Chemotherapy: FOLFOX, XELOX, DCF for gastric; carboplatin/paclitaxel for esophageal. Second-line: paclitaxel ± ramucirumab; irinotecan.
Targeted & Immunotherapy
- Trastuzumab: HER2+ gastric/GEJ — first-line with chemo (ToGA trial). Median OS improvement ~2.7 months
- Ramucirumab: VEGFR2 — second-line gastric (RAINBOW, REGARD trials). Paclitaxel + ramucirumab is standard second-line
- Pembrolizumab: PD-L1 CPS ≥10 — first-line gastric (KEYNOTE-590). Meaningful survival benefit with manageable toxicity
- Nivolumab + chemo: First-line gastric/GEJ adenocarcinoma (CheckMate 649)
Palliative Procedures
- SEMS for dysphagia: Esophageal obstruction — covered stent preferred; rapid dysphagia relief[4]
- SEMS for GOO: Duodenal stent for gastric outlet obstruction
- EUS-guided gastrojejunostomy: Emerging alternative to surgical bypass for GOO[18]
- Venting gastrostomy (PEG): For GOO with intractable vomiting — decompression, not feeding
- IPC / paracentesis: For malignant ascites from peritoneal carcinomatosis[19]
- Hemorrhage management: IR embolization, endoscopic treatment — know if prior hemorrhage occurred
When Therapy Makes Sense
Evidence-based criteria for continuing disease-directed therapy. This is not about giving up or holding on — it's about reading the data correctly.
Palliative referral delays are well-documented in gastroesophageal cancer. Early concurrent palliative care improves quality of life and reduces aggressive end-of-life interventions without reducing survival. The following criteria identify patients for whom disease-directed therapy still offers meaningful benefit.[2]
- 01HER2+ gastric/GEJ with trastuzumab first-line (ECOG 0–2): The ToGA trial showed meaningful OS benefit (13.8 vs 11.1 months). Targeted therapy is well-tolerated. Even in patients approaching hospice eligibility, if HER2+ and functional, trastuzumab adds real time with manageable toxicity.
- 02PD-L1 CPS ≥10 gastric with pembrolizumab first-line: KEYNOTE-590 and CheckMate 649 demonstrated meaningful survival with manageable toxicity in this biomarker-selected population. Immunotherapy can produce durable responses even in advanced disease.
- 03Esophageal adenocarcinoma — ramucirumab + paclitaxel second-line (ECOG 0–1): RAINBOW trial showed OS benefit. Appropriate for patients with adequate performance status who have progressed on first-line and wish to continue therapy.
- 04Dysphagia palliation with SEMS placement: Even in hospice-eligible patients, stent placement that restores ability to swallow liquids is a comfort intervention. This is not disease-directed therapy — it is a dignity-preserving procedure that extends quality of life.
- 05Patient goals explicitly include life-prolongation with full prognosis understanding: A well-informed patient who understands their prognosis and chooses active treatment should receive it without judgment. Adequate nutritional status to tolerate therapy (albumin >2.5, no refractory obstruction) is a prerequisite.
When It Doesn't
Knowing when treatment stops helping is not clinical failure. It is the most important clinical skill in this disease.
Gastroesophageal cancers have some of the highest rates of aggressive end-of-life care in oncology — chemotherapy within 14 days of death, ICU admissions in the last month, and late hospice referral (median LOS <7 days in many series). Recognizing futility thresholds earlier is not giving up. It is honest medicine.[2]
- 01ECOG ≥3: No evidence of benefit from any systemic therapy at this performance status. Toxicity dominates and survival is not extended. This threshold applies to all regimens in gastroesophageal cancer.
- 02Progression through ≥2 lines of chemotherapy: Response rates fall below 10% at third-line and beyond. Toxicity burden is disproportionate to any measurable benefit. Clinical trial enrollment is reasonable for motivated patients; standard therapy is not.
- 03Dysphagia to liquids (Mellow-Pinkas grade 4) with SEMS failure or not a candidate: Complete obstruction with no salvage option. Oral medication route is lost. This is a hospice-defining moment.
- 04Peritoneal carcinomatosis with refractory GOO: Surgery carries high perioperative mortality and does not improve long-term outcomes. Medical management with octreotide, haloperidol, dexamethasone, and venting gastrostomy is the evidence-based approach.
- 05Serum albumin <2.5 g/dL with progressive decline: Nutritional failure is a marker of systemic failure, not a fixable problem. It reflects the cachexia-inflammatory axis that feeding cannot reverse.[24]
- 06Estimated survival <3 months with patient goals shifting to comfort: When a fully informed patient prioritizes quality over quantity, that is not giving up. It is clarity.
📋 The Feeding Conversation — Say It Plainly
Artificial nutrition via PEG in end-stage gastroesophageal cancer does not extend survival. In peritoneal disease it can cause significant harm — increased ascites, aspiration, discomfort. A venting gastrostomy is comfort care. A feeding gastrostomy at this stage is not. Families need this distinction made plainly, with compassion, at enrollment — not at crisis.[7]
Out-of-the-Box Approaches
Evidence-graded integrative, interventional, and complementary approaches. Grade A = RCT; B = multi-observational/meta-analysis; C = limited clinical, strong preclinical; D = expert opinion.
Acupuncture for Dysphagia, Nausea & Pain
Grade BPC6 (Neiguan) for nausea; disease-specific protocols for pain and dysphagia
Evidence in upper GI cancer supports acupuncture for nausea (PC6 point has Grade A evidence for chemotherapy-induced nausea), post-SEMS discomfort, and cancer pain as adjunct to opioids. Systematic reviews show moderate benefit for cancer-related nausea and quality of life improvement. Safe when performed by trained practitioners; avoid anticoagulated or thrombocytopenic patients.
Mind-Body / MBSR for Anxiety & QoL
Grade B8-week MBSR program or adapted bedside mindfulness; daily guided sessions 15–20 min
Dysphagia and feeding failure create significant anxiety in both patients and families. Mindfulness-based stress reduction specifically reduces catastrophizing around eating difficulty. Multiple RCTs in advanced cancer show MBSR improves anxiety, depression, and quality of life. Adapted bedside protocols are feasible even in low-performance-status patients. Audio-guided sessions can be used independently.
Ginger for Nausea
Grade A1 g/day PO in capsule or tea form; standardized extract preferred
Strong RCT evidence for chemotherapy-related nausea. 5-HT3 antagonism and substance P modulation. Safe, minimal interactions at standard doses. Particularly important in this diagnosis where nausea is nearly universal. Capsule form preferred for consistent dosing; ginger tea acceptable for comfort. Avoid doses >2 g/day in patients with bleeding risk.[31]
Palliative Radiation for Dysphagia
Grade BBrachytherapy (single-dose 12–15 Gy) or EBRT (20–30 Gy in 5–10 fractions)
For patients not amenable to SEMS (proximal tumors, post-stent failure), brachytherapy or short-course EBRT provides dysphagia relief in 50–70% of cases. The ROCS trial showed RT after SEMS did not reduce dysphagia recurrence but did reduce bleeding events (HR 0.52). Hospice-compatible with appropriate goals discussion and short treatment courses.[4][50]
SEMS as Comfort Intervention
Grade ACovered or partially covered SEMS; placement by interventional endoscopy
Restoring the ability to swallow saliva and liquids is one of the most dignity-preserving comfort interventions available. Technical success >93%. Dysphagia scores drop from median 3 to 1 within one week. Even in hospice-eligible patients, this conversation belongs in goals-of-care planning. A stent that lets someone sip water is not futile care — it is comfort care.[6][8]
Nutritional Counseling for Comfort Eating
Grade CSmall frequent offerings of texturally modified foods; comfort sips of favorite beverages
Eating as pleasure and social connection, not caloric target. Small, appealing offerings — a sip of coffee, a spoonful of ice cream, a taste of a cultural favorite. This reframes the feeding conversation from nutritional failure to quality of life. Families need explicit permission to shift from feeding to comfort eating. Registered dietitian consultation can help calibrate expectations and reduce family distress.[7]
Natural & Herbal Options
Evidence grading, dosing where supported, drug interaction flags, and explicit contraindications specific to this diagnosis. Patients will use supplements — this section helps you have the right conversation.
"Patients are going to use supplements whether we ask or not. The conversation is: 'I want to know what you're taking — not to judge you, but because some of these interact with your pain medications and blood thinners.' Say it plainly. Most of the time they're relieved someone asked."
— Waldo, NP
| Herb / Supplement | Evidence Grade | Typical Dose | Potential Benefit | ⚠ Interactions / Contraindications |
|---|---|---|---|---|
| Ginger | Grade B | 1 g/day PO capsule or tea | Nausea — 5-HT3 antagonism; chemotherapy-related and cancer nausea. Particularly important in this diagnosis where nausea is universal[31] | Anticoagulants (additive antiplatelet at >2 g/day); avoid in active GI hemorrhage; caution 2–4 weeks post-SEMS |
| Slippery Elm | Grade C | 400–500 mg capsule TID or bark tea (1 tbsp/cup) | Mucilaginous coating for esophageal irritation and dysphagia discomfort. Popular in this patient population for soothing esophageal mucosa | No significant drug interactions. May slow absorption of oral medications — space 2 hours. Safe in hospice population |
| Aloe Vera Juice | Grade C | 30–60 mL inner leaf gel juice BID | Some esophageal mucosa soothing data; anti-inflammatory properties may reduce GERD-related discomfort | Caution with electrolyte imbalance in cachectic patients. Laxative effect in whole-leaf preparations — use inner leaf only. Avoid if GOO present |
| Glutamine | Grade C | 10–30 g/day PO in divided doses | Mucosal healing during radiation esophagitis. Limited end-stage evidence but commonly used for oral mucositis and esophageal irritation | Hepatic failure — glutamine can worsen encephalopathy. No significant drug interactions. Safe at standard doses in hospice |
| Melatonin | Grade C | 3–10 mg PO at bedtime | Sleep, QoL improvement, some gastroprotective signal in gastric mucosa preclinically. Most consistent benefit is as sleep aid[33] | Warfarin (potentiates anticoagulant — monitor INR). Sedatives (additive). Fluvoxamine (17× increase in levels). Safe at standard doses |
🚫 Avoid in This Diagnosis
- High-dose fish oil + Ginkgo biloba: Antiplatelet — compounded hemorrhage risk in patients with tumor erosion risk. This is particularly dangerous in esophageal cancer with vascular proximity
- St. John's Wort: CYP3A4 inducer — destroys ramucirumab and any remaining targeted therapy blood levels. Contraindicated with virtually all cancer therapeutics
- Licorice root in large quantities: Raises blood pressure, causes hypokalemia — worsens electrolyte imbalance in cachectic patients, interacts with dexamethasone
- Cascara and stimulant laxatives in GOO patients: Worsen obstruction symptoms by increasing peristalsis against a mechanical block
- Any supplement with significant aspiration risk in liquid form: In dysphagia patients, thick viscous liquids or large capsules carry aspiration risk — assess swallowing function before recommending any oral supplement
Timeline Guide
A guide, not a prediction. Every patient's trajectory is shaped by histology, molecular profile, treatment response, and comorbidities.
HER2+ gastric patients on trastuzumab may have a longer trajectory. Signet-ring cell and peritoneal carcinomatosis shorten it dramatically. Esophageal SCC in the upper third behaves differently from GEJ adenocarcinoma. Read the pathology and the molecular profile before estimating timeline.[1][2]
YRS–
MOS
MOS
Post-Surgical Resection / Adjuvant Phase
- Curative-intent resection performed (esophagectomy or gastrectomy); know what anatomy remains
- Adjuvant chemotherapy or chemoradiation ongoing; surveillance endoscopy scheduled
- Functional but fatigue and nutritional challenges ongoing — dumping syndrome if gastrectomy
- Palliative care integration recommended from this stage; advance care planning conversations begin
MOS–
1 YR
1 YR
Metastatic / Locally Advanced — Active Treatment
- Metastatic or locally advanced unresectable disease on first- or second-line systemic therapy
- SEMS placed if dysphagia progressing; weight loss significant and ongoing
- HER2+ patients on trastuzumab may have longer trajectory here
- GOO symptoms developing in gastric; peritoneal disease may be emerging on imaging
- Second-line therapy beginning; performance status declining to ECOG 1–2
WKS–
MOS
MOS
Hospice Transition / Preterminal
- Progression through multiple lines; dysphagia advancing from soft foods to liquids
- GOO causing increasing nausea and vomiting; peritoneal disease with ascites
- ECOG declining to 2–3; hospice enrollment most appropriate at this transition — the window is short[3]
- Family feeding conflict intensifies; comfort kit preparation essential
- Convert medications to SQ route before oral route is lost
DAYS–
WKS
WKS
Active Dying — Pre-Active Phase
- Complete or near-complete dysphagia; GOO with intractable vomiting
- Ascites requiring frequent paracentesis; inability to maintain oral medications
- Convert all medications to SQ route; CSCI for pain and symptom management
- Hemorrhage risk highest at this stage — tumor erosion into vasculature
- Family at maximum distress; caregiver burnout accelerating
HRS–
DAYS
DAYS
Final Hours
- Complete inability to swallow; venting gastrostomy drainage ongoing if in place
- Cheyne-Stokes breathing; mottling of extremities; unresponsive or minimally responsive
- Hemorrhage comfort protocol in place if esophageal tumor — have midazolam drawn, dark cloth at bedside, family briefed
- Auditory awareness may persist — speak to the patient, not about them
- Presence is the clinical priority. The family needs you present and calm.
Medications to Anticipate
Symptom-targeted pharmacology for esophageal and gastric cancer. What to have in the comfort kit, what to titrate first, and what the evidence supports.
Pain, nausea, and obstruction drive medication decisions in this diagnosis. Dysphagia eliminates the oral route early — plan for SQ conversion before crisis. Octreotide is transformational in GOO and underused. The hemorrhage comfort protocol must be written and rehearsed before the event.[20][21]
| Drug | Class / Target Symptom | Starting Dose | Notes / Cautions |
|---|---|---|---|
| Morphine / Hydromorphone | Opioid / Pain | Morphine 2.5–5 mg SQ q4h ATC; Hydromorphone 0.5–1 mg SQ q4h | SQ preferred as dysphagia advances. Do not wait for patient to report pain — assess behaviorally if communication is limited. Fentanyl patch for stable pain with swallowing impairment. Rescue dose = 10–15% of 24h total.[28] |
| Octreotide | Somatostatin / GOO & MBO | 100–200 mcg SQ q8h; or 300–600 mcg/24h CSCI | Reduces GI secretions, decreases vomiting volume. Transformational in obstruction management. First-line for high-output nausea/vomiting in GOO. Every hospice team should have it available. Grade B[20] |
| Haloperidol | Antiemetic / GOO nausea | 1–2 mg SQ q8h; 0.5 mg PRN q4h | Superior to metoclopramide when obstruction present. No prokinetic activity — safe in mechanical GOO. Best tolerated central antiemetic in hospice. Grade B |
| Dexamethasone | Anti-inflammatory / GOO adjunct | 4–8 mg SQ/IV daily AM | Reduces bowel wall edema; may temporarily relieve partial obstruction. Appetite stimulant. Pain adjunct. Short-term benefit — taper if >2 weeks.[29] |
| Hyoscine Butylbromide / Glycopyrrolate | Anticholinergic / Secretions | Hyoscine 20 mg SQ q4–6h; Glycopyrrolate 0.2 mg SQ q4h | GI secretion reduction, cramping from GOO, terminal secretions. Glycopyrrolate preferred in conscious patients — no CNS effects. |
| Midazolam | Benzodiazepine / Emergency | 5–10 mg SQ/buccal PRN | Terminal agitation and hemorrhage emergency. MUST be in comfort kit drawn and labeled for esophageal cancer with central tumor or vascular proximity. ⚠ Essential — do not omit |
| Ondansetron | 5-HT3 / Nausea adjunct | 4–8 mg PO/SL/IV q6–8h PRN | Adjunctive for chemotherapy-associated and post-procedural nausea. Less effective for obstructive nausea than haloperidol. QT prolongation risk at high doses. |
| Lorazepam | Benzodiazepine / Anxiety | 0.5–1 mg PO/SQ q4–6h PRN | Dysphagia and feeding failure generate profound anxiety in both patients and families. Adjunctive role — not monotherapy for nausea. |
| Pantoprazole / Omeprazole | PPI / Acid suppression | Pantoprazole 40 mg IV/SQ daily; Omeprazole 20 mg PO daily | Reduces SEMS irritation. Continue even in hospice if stent in place — gastric acid against a metal stent causes significant discomfort. IV pantoprazole when oral route lost. |
🌿 Symptom Management Decision Tree
Evidence-based · Hospice-adaptedSelect a symptom below to begin
What is the primary symptom to address?
🚨 Comfort Kit Must-Haves — Esophageal & Gastric Cancer
For esophageal cancer patients with central tumors or known vascular proximity — catastrophic hemorrhage (hematemesis) is a possible terminal event. Midazolam 5–10 mg SQ must be drawn, labeled, and at the bedside before this event. Dark red or brown towels at bedside. Family briefed on what to do — stay present, administer midazolam, call the nurse. Do not call 911. This conversation happens at a good visit, not in the middle of a crisis. Write it in the care plan. Every visit.
Clinician Pointers
High-yield clinical pearls for the hospice team. The things not in the textbook — learned at the bedside over years of clinical experience.
1
Three things define every visit — not eating, in pain, family panicking about both
Address all three in that order before anything else. Do not get sidetracked by vital signs or medication reconciliation before you have acknowledged and addressed these three problems. The family needs to hear you name them out loud.
2
SEMS occlusion is a clinical emergency
Fever, worsening dysphagia, and odynophagia in a stented patient = stent failure until proven otherwise. Have a plan for who to call before it happens — interventional gastroenterology, the stenting team, or the on-call specialist. Document this plan in the chart at enrollment.[6]
3
GOO management is medical, not surgical
4
5
Hemorrhage preparedness in esophageal cancer
Central tumors erode into major vessels — aorta, pulmonary artery, azygos vein. Have the conversation with the family. Have the medications drawn. Have the protocol written. Dark towels at bedside. Midazolam labeled. Family briefed at a good visit, not during the crisis.
"I've sat with families who kept fighting to get their dad to eat while he was actively dying. They weren't cruel — they were terrified. 'If he eats, he lives' is how the human brain is wired. Your job is to gently unwire that. 'He's not starving — his body is shutting down. Feeding him now would cause harm, not comfort.' Say it. Don't soften it into uselessness."
— Waldo, NP · Terminal2
Psychosocial & Spiritual Care
Existential distress, depression screening, spiritual assessment, and goals-of-care communication. The symptom burden you can't see on a vitals sheet.
Psychosocial and spiritual distress in terminal illness is as clinically significant as pain — and far more likely to go unaddressed. In esophageal and gastric cancer, the loss of eating is not just a physical symptom. It dismantles something fundamental about human identity and connection.[26]
The Loss of Eating as Identity and Connection
Food is how humans express love, celebrate, grieve, and belong. Losing the ability to eat dismantles something fundamental. In many Hispanic, Asian, and other cultures, food preparation and shared meals are central to family identity — the caregiver who can no longer feed their loved one is grieving something specific and profound. Address this directly and with cultural sensitivity.
Psychological Distress Screening
Depression — Screen Every Patient
Grade BSingle-question screen: "Are you depressed?" has 100% sensitivity in terminally ill populations when phrased directly.
- PHQ-2: "Little interest/pleasure" + "Feeling down/hopeless" — score ≥3 warrants full PHQ-9
- Mirtazapine 7.5 mg QHS: First-line in hospice — addresses depression, insomnia, and anorexia simultaneously
- Patients who cannot eat are particularly vulnerable to hopelessness and social isolation[30]
Diagnosis Shock & Younger Patients
Grade B- Diagnosis shock: Esophageal and gastric cancers often present late with nonspecific symptoms (reflux, indigestion, bloating) attributed to benign causes for months. Patients and families often carry anger and grief about delayed diagnosis. Acknowledge it without defensiveness.
- Younger gastric cancer patients: Diffuse gastric cancer (CDH1) often strikes people in their 30s and 40s. The grief is categorically different. Do not treat a 38-year-old with gastric cancer the same as a 72-year-old.
- Body image and cachexia: The visible wasting is dramatic and distressing. Address it with clinical directness — cachexia is not starvation, and forcing food causes harm, not healing.
Spiritual Assessment
In many faith traditions and cultures, food is central to care, love, hospitality, and religious expression. The inability to eat together, to share a meal, or to receive the Eucharist is not just physical — it is a spiritual loss. Chaplaincy referral is essential when food rituals are disrupted by disease. Use the FICA framework: Faith/beliefs, Importance, Community, Address. Ask: "What gives you strength during this time?"[26]
Family Caregiver Feeding Conflict
The caregiver who cannot feed their loved one often feels like they are failing. This is one of the most common and most painful family dynamics in this diagnosis. A nationwide Japanese survey found 72% of bereaved family members had unmet needs for nutritional support education, and the top eating-related distress was feeling they had to force the patient to eat to prevent death.[26] Address this every visit. Explicitly.
Goals-of-Care Framing
Opening the Conversation
- "What is your understanding of where things stand with your illness?"
- "What are you hoping for?" — surfaces values, not just preferences
- "What are you most afraid of?" — identifies what goals-of-care planning must address
- "Dying at home without a tube" is almost universally the operative goal — name it, protect it, build the entire care plan around it
Communication Pitfalls
- Don't say "there's nothing more we can do": There is always more to do — it just looks different now
- Don't conflate hospice with giving up: Frame around what hospice adds
- Don't have this conversation standing up: Sit down. Make eye contact. Leave silence.
- Involve the family separately when needed: Patients and families often have different goals
Suicidal Ideation & Hastened Death Requests
Passive wish for death ("I'm ready to go") is common and often existentially appropriate — it is not the same as active suicidal ideation. Assessment requires careful distinction: passive wish for death (common, often appropriate), active suicidal ideation with plan (requires immediate psychiatric engagement), and medical aid in dying requests (legal in some jurisdictions — requires specific protocol).
Clinical Pearl
"Upper GI cancers take away the most human thing we do — eat together. The clinical and the emotional are the same problem. When you address the feeding conversation, you are not just managing a symptom — you are helping a family grieve a loss that started the moment the diagnosis was given."
"Every hospice nurse has been in a room where a daughter is sobbing because her mother won't eat. And the mother is exhausted and just wants to be left alone to rest. The food battle is usually a proxy war for grief. Name the grief. That's the actual clinical intervention."
— Waldo, NP · Terminal2
Family Guide
Plain language for families. Share, print, or read aloud at the bedside.
Your loved one has a cancer of the esophagus or stomach that has reached a stage where the focus of care is on comfort, dignity, and quality of life. The most visible challenge is likely difficulty eating and swallowing. This is the disease — not a choice, not dehydration, not something that can be fixed by trying harder. Your hospice team is here to manage symptoms, reduce suffering, and support you through this.
What You May See
- Difficulty swallowing: Even liquids may be difficult or impossible. This is the disease progressing, not dehydration. Your nurse will explain what is happening.
- Nausea and vomiting: May be related to the stomach or bowel being blocked. Your nurse needs to know if this is severe or won't stop with medications.
- Severe weight loss and muscle wasting: This is the cancer changing how the body uses nutrition. Feeding does not reverse it — this is called cachexia.
- Abdominal swelling: If fluid is accumulating, your nurse will explain the drainage procedure and whether a permanent drain is appropriate.
- Profound fatigue: Sleeping most of the day is expected and does not mean something went wrong.
- Pain when trying to eat or drink: Do not push food if it causes pain. Comfort sips of favorite beverages if tolerated are enough.
How You Can Help
- Do not push food or large volumes of fluid: This causes suffering, not strength. Small sips of favorite drinks if tolerated are enough.
- If a drainage tube is in place: Your nurse will teach you how to manage it. Call if it stops draining or the output changes significantly.
- Keep the head of the bed elevated 30–45 degrees: This reduces reflux and vomiting discomfort.
- Report immediately: If vomiting becomes severe, turns dark or bloody, or will not stop with medications — call the nurse, not 911.
- Be present without needing to fix the eating: Sitting with someone while they cannot eat is an act of profound love.
- Take care of yourself: You cannot pour from an empty cup. Call us when you need support — not just when the patient does.
📞 Call the nurse immediately if you see:
Vomiting blood or dark material that looks like coffee grounds — call the nurse immediately, stay with your loved one, use the dark towels at bedside, give the comfort medication the nurse showed you. Sudden severe chest or abdominal pain that is new or different. Inability to be woken. Stent in place and sudden complete inability to swallow even saliva — possible stent failure, needs urgent attention. If on hospice with DNR, do not call 911 unless the nurse directs you to.
🙏 You cannot fix the fact that they cannot eat. You cannot make the tube go away. What you can do — being present, sitting beside them, holding their hand — is not nothing. It is everything. The data is clear: patients who have people present do better — not just emotionally, but clinically. You are part of the care team whether you know it or not.
Waldo's Top 10 Tips
Clinical field wisdom from 12+ years at the bedside. The things you learn after doing this long enough. Not guidelines — real.
- 01Three things define every visit with an esophageal or gastric cancer patient: they are not eating, they are in pain, and the family is panicking about both. Address in that order — every time, every visit, no exceptions. Before you open the med list, before you check vitals, before you do anything else — sit down, look at the family, and say: "I can see he's not eating. Let me explain what's happening and what we can do about the pain. And let me talk to you about what you're feeling watching this." That's your opening. That's your framework. If you do nothing else, do that.
- 02SEMS occlusion is the clinical emergency in esophageal cancer, and it will blindside you if you don't have a plan. The patient was doing fine — swallowing liquids, taking meds — and then suddenly they can't even handle their own saliva. Fever, worsening dysphagia, odynophagia — that's stent failure until proven otherwise. Know the signs. Know who to call — the interventional GI team, the stenting center, whoever placed it. Have that number in the chart at enrollment. Write it down. Don't figure it out at 2 AM when the patient is drowning in their own secretions.
- 03Octreotide in GOO is the most underused drug in this diagnosis. I have watched patients go from vomiting 10 times a day to comfortable in 48 hours on octreotide. It reduces GI secretions, decreases vomiting volume, and when you combine it with haloperidol and dexamethasone, you have a GOO regimen that transforms quality of life. Every hospice pharmacy should stock it. Every hospice nurse should know how to run it in a CSCI. If your formulary doesn't carry it, fight for it. This drug is the difference between a patient dying in misery from intractable vomiting and a patient dying in comfort.
- 04The feeding conversation is a clinical skill, and most of us were never trained for it. Families need to hear three things clearly: cachexia is not starvation, forcing food causes harm, and comfort sips of a favorite drink are legitimate and loving. Say it plainly at enrollment, not at crisis. "His body can no longer use food the way it used to. This is the cancer, not him, and not you. A sip of his favorite coffee for pleasure — that's a gift you can still give him. A tube that pumps nutrition into a body that can't use it — that's not a gift. That causes suffering." Rehearse this. Say it to yourself in the car before the visit. Because the family's face when they hear it will test you, and you need to hold steady.
- 05Hemorrhage preparedness in esophageal cancer is not optional — it is non-negotiable. Central tumors erode into the aorta, the azygos, the pulmonary artery. When it happens, it happens fast, it is terrifying, and it is almost always fatal in minutes. Have midazolam drawn — 5 to 10 mg SQ in a labeled syringe at the bedside. Have dark red or brown towels right there, not in a closet. Brief the family at a good visit: "If this happens, here's what you do — use the towels, give the medication from this syringe, stay with him, and call us. You won't be alone." Write it in the care plan. Check it at every visit. This is the one thing you must not leave to chance.
- 06GOO surgery at end-stage peritoneal disease kills. I've seen surgeons talk about "just a bypass" in patients with a belly full of tumor nodules, albumin of 2.1, and an ECOG of 3. The perioperative mortality in this population is 15–30%. The median survival after palliative surgery for GOO in peritoneal carcinomatosis is measured in weeks, not months. Know the data. Redirect to medical management — octreotide, haloperidol, dexamethasone, venting tube. Be the voice of honest medicine when the surgeon is still operating from hope instead of evidence. That's your job. It's not comfortable. Do it anyway.
- 07The venting gastrostomy conversation requires precision. Families hear "tube in the stomach" and immediately think "feeding tube." They confuse venting with feeding, and that confusion causes suffering in both directions — either they resist a comfort intervention because they've been told "no more tubes," or they expect it to nourish their loved one and grieve when it doesn't. Be explicit: "This tube drains the stomach. It relieves the nausea and vomiting. It does not feed. It is a comfort device, like having an exhaust valve." Say it three times. Write it down. Repeat it at the next visit.
- 08Pain in esophageal and gastric cancer is often undertreated because swallowing medications is difficult and nobody planned for it. The patient can't take their morphine tablet, so they go hours without pain control, and by the time someone calls, they're in crisis. Convert to SQ route before the patient cannot swallow, not after. At enrollment, if the dysphagia score is 2 or higher, have the SQ conversion plan already written. Morphine CSCI. Hydromorphone SQ PRN. Fentanyl patch for baseline. Don't wait for the crisis — anticipate it.
- 09Cultural humility and food. In many of your patients' cultures — Hispanic, Asian, Middle Eastern, African American, Mediterranean — food is love. It's not a metaphor. It is literally how love is expressed, how community is built, how grief is processed. The caregiver who cannot feed their dying person is experiencing a specific cultural grief that goes beyond medical nutrition. You need to acknowledge it by name. "I can see that feeding him has always been your way of caring for him. That hasn't changed — it just looks different now. Sitting with him, holding his hand, playing his favorite music — that is feeding his spirit." Don't skip this because it doesn't feel clinical. It is the most clinical thing you'll do all visit.
- 10Caregiver burnout is accelerated in this diagnosis because the visible symptoms are dramatic and the family feels helpless. They watch the person they love waste away, unable to eat, vomiting, in pain — and the one thing they want to do (feed them) is the one thing that causes harm. That's a particular cruelty of this disease. Assess the caregiver separately at every visit. Ask: "How are you sleeping? Who is helping you? When did you last eat?" Connect them to support before they collapse — respite care, caregiver support groups, the hospice social worker. The caregiver who burns out becomes the next patient. Prevent it. That's not optional in this diagnosis. That's standard of care.
— Waldo, NP
References
Peer-reviewed citations. Based on articles retrieved from PubMed. All PMIDs hyperlinked. Evidence levels assigned by article type.
1
DeCarli K, Guyer D, Almhanna K. Palliative care for patients with gastroesophageal cancer at all stages: a narrative review. Ann Palliat Med. 2024;13(3):641–653.
2
Lee A, Khulusi S, Watson R. Gastroesophageal cancer patients need earlier palliative intervention — Using data to inform appropriate care. Eur J Oncol Nurs. 2019;40:126–130.
3
Sunde B, Lindblad M, Malmström M, et al. Health-related quality of life one year after the diagnosis of oesophageal cancer: a population-based study. BMC Cancer. 2021;21(1):1277.
4
Adamson D, Byrne A, Porter C, et al. Palliative radiotherapy after oesophageal cancer stenting (ROCS): a multicentre, open-label, phase 3 RCT. Lancet Gastroenterol Hepatol. 2021;6(4):292–303.
5
Adamson D, Blazeby J, Porter C, et al. Palliative radiotherapy combined with stent insertion — the ROCS RCT (HTA report). Health Technol Assess. 2021;25(31):1–144.
6
Didden P, Reijm AN, Erler NS, et al. Fully vs. partially covered SEMS for palliation of malignant esophageal strictures: the COPAC study. Endoscopy. 2018;50(10):961–971.
7
Warren A, Buss MK. Death by Chocolate: The Palliative Management of Dysphagia. J Palliat Med. 2021;25(6):1004–1008.
8
Kim JY, Kim SG, Lim JH, et al. Clinical outcomes of esophageal stents in patients with malignant esophageal obstruction. J Dig Dis. 2015;16(10):575–584.
9
Kopecky K, Monton O, Rosman L, Johnston F. Palliative interventions for patients with advanced gastric cancer: a systematic review. Chin Clin Oncol. 2022;11(6):47.
10
Wierzbicka A, Shah T. Advancing care in malignant gastric outlet obstruction: a contemporary review. Curr Opin Gastroenterol. 2025;41(6):409–415.
11
Ahmed O, Lee JH, Thompson CC, Faulx A. AGA Clinical Practice Update on Malignant Alimentary Tract Obstruction. Clin Gastroenterol Hepatol. 2021;19(9):1780–1788.
12
Minoura T, Otani K, Harada S, et al. Practice Patterns of Medications for Patients With Malignant Bowel Obstruction. J Pain Symptom Manage. 2017.
13
O'Connor B, Creedon B. Pharmacological treatment of bowel obstruction in cancer patients. Expert Opin Pharmacother. 2011.
14
Mercadante S, Porzio G, Fulfaro F. Medical treatment for inoperable malignant bowel obstruction: a qualitative systematic review. J Pain Symptom Manage. 2007.
15
Duffy T, Kochanczyk M. Practical cancer cachexia management in palliative care — a review. Curr Opin Support Palliat Care. 2023;17(3):177–185.
16
Amano K, Maeda I, Ishiki H, et al. Effects of enteral nutrition and parenteral nutrition on survival in patients with advanced cancer cachexia. Clin Nutr. 2020;40(3):1168–1175.
17
Amano K, Maeda I, Morita T, et al. Eating-related distress and need for nutritional support of families of advanced cancer patients. J Cachexia Sarcopenia Muscle. 2016;7(5):527–534.
18
Amano K, Maeda I, Morita T, et al. Need for nutritional support, eating-related distress of terminally ill patients with cancer. BMJ Support Palliat Care. 2015;6(3):373–376.
19
Rizzo GEM, Arini A, Busacca A, et al. The Role of Endoscopy in Palliation of Pancreatico-Biliary Cancers. Cancers (Basel). 2023;15(22):5367.
20
Lussier D, Portenoy RK. Adjuvant analgesics in cancer pain management. Oncologist. 2004;9(5):571–591.
21
Morita T, Kuriya M, Miyashita M, et al. Symptom burden and achievement of good death of elderly cancer patients. J Palliat Med. 2014;17(8):887–893.
22
Cai K, Chen J, Li N, Feng L. Ginger-based TCM formula for chemotherapy-induced GI reactions: a randomized double-blind placebo-controlled trial. Anticancer Agents Med Chem. 2026;26(2):217–224.
23
Bruera E. Pharmacological treatment of cachexia: any progress? Support Care Cancer. 1998;6(2):109–113.
24
Ishii K, Tsubosa Y, Niihara M, et al. Palliative radiotherapy to maintain outpatient status in elderly patients with esophageal carcinoma. Ann Palliat Med. 2020;10(2):1779–1783.
25
Brown JL, Aggarwal A, Chalder T, et al. Understanding Cancer Cachexia and Its Implications in Upper Gastrointestinal Cancers. Curr Treat Options Oncol. 2022.
terminal2.care content is for educational purposes and is not a substitute for clinical judgment. Based on articles retrieved from PubMed. All PMIDs hyperlinked. © Terminal2 | terminal2.care
Private Notes
Session notes — not saved to any server. Clears when you close the tab.
Use this space for visit notes, clinical reminders, or patient-specific observations. This text is stored only in your browser session.